CLYM
Climb Bio, Inc. Health Care Pharmaceutical Preparations Russell 3000
$10.25Close
$489.6MMarket cap
$1.64 – $17.8452-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 98 · stronger than 98% of stocks over 12 months
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 43% below its 52-week high
- Distribution down-day volume 1.8× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
43%
1wk
up 0.6%
price change
1mo
down 10.6%
price change
12-month return
up 415%
market up 11% ·
its own up 382%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.1×
price / book
Earnings yield
down 15.0%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 32%
return on equity
Free cash margin
—
-$54.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
8.1%
$0.83 a day · 2×ATR $8.59
RS
98 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
0.5×
vs 50-day average
Up/down volume
0.57
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 6, 2026
Last shock
Oct 26, 2026-14% in one session2.4× volumeon an SEC filing+16% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$20.9M | -$35.7M | -$45.1M | -$40.3M | -$82.0M | -$67.9M |
| Net income | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| Earnings per share | -$9.45 | -$3.87 | -$1.72 | -$1.30 | -$1.53 | -$0.88 |
| Free cash flow | -$14.1M | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.5M |
| Cash | $20.5M | $46.9M | $43.6M | $93.1M | $87.2M | $35.7M |
| Shareholders' equity | -$25.0M | $167.2M | $128.7M | $107.6M | $211.9M | $160.5M |
| Shares outstanding | 3.42m | 26.57m | 26.57m | 27.70m | 67.26m | 47.77m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 25, 2025 | Annual ↗ | Dec 31, 2024 | 84d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 15, 2024 | Quarterly ↗ | Mar 31, 2024 | 45d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 26, 2026 | Regulation FD · Other events ↗ |
| Oct 23, 2026 | Regulation FD · Other events ↗ |
| Sep 3, 2026 | Regulation FD ↗ |
| Aug 14, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 1, 2026 | Director or officer change ↗ |
| Jun 12, 2026 | Material agreement · Other events ↗ |
| Jun 11, 2026 | Other events ↗ |
| Jun 8, 2026 | Director or officer change · Shareholder vote ↗ |
| Jun 5, 2026 | Other events ↗ |
| May 7, 2026 | Results ↗ |
| May 5, 2026 | Regulation FD ↗ |